Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Clinical evidence

LDA1

56 evidence topics · 4 sources

Objective
Location and study date
Study identifiers, dates, and status
ItemRegistry record
Other study ID“LDA1”
Phase“Phase 2”
Study start“2008-02”
Primary completion (actual)“2011-04-14”
Study completion (actual)“2012-09”
First posted (estimated)“2009-06-15”
Results first posted“2021-12-08”
Last update posted“2023-07-12”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using State-Trait anxiety inventory score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Registry participant flow
Period and statusFull dose LSD (200 mcg), blinded stage 1Active placebo LSD (20 mcg), stage 1Full dose LSD (200 mcg), open-label stage 2
Stage 1 started“8”“4”“0”
Stage 1 completed“7”“4”“0”
Stage 1 not completed: adverse event“1”“0”“0”
Stage 2 started“0”“0”“3”
Stage 2 completed“0”“0”“3”
Baseline characteristics
Registry baseline characteristics
CharacteristicFull dose LSD (200 mcg)Active placebo LSD (20 mcg)Total
Participants“8”“3”“11”
Age, years, mean (SD)“49.6(8.4)”“57.4(9.9)”“51.7(9.1)”
Female“3”“1”“4”
Male“5”“2”“7”
History of suicidal tendencies: none“8”“1”“9”
History of suicidal tendencies: mild“0”“2”“2”
Metastatic breast carcinoma“3”“1”“4”
Metastatic gastric carcinoma“2”“0”“2”
Plasmocytoma“1”“0”“1”
Non-Hodgkin's Lymphoma“0”“1”“1”
Celiac Disease“0”“1”“1”
Parkinson's Disease“1”“0”“1”
Bechterew's Disease“1”“0”“1”
Baseline STAI scores (registry primary outcome at baseline, visit 4)
STAI subscale, mean (SD)Full dose LSD (200 mcg), n = 8Active placebo LSD (20 mcg), n = 3
STAI-state“53.1(4.7)”“47.7(7.7)”
STAI-trait“53.2(4.3)”“43.3(7.0)”
Efficacy results
Primary endpoint: STAI at 2 months after the second session (registry)
STAI subscale, mean (SD)Full dose LSD (200 mcg), n = 8Active placebo LSD (20 mcg), n = 3
STAI-state“41.5(3.2)”“51.7(5.3)”
STAI-trait“45.2(3.7)”“49.0(6.1)”
Health-related quality of life and patient-reported outcomes
Safety results
Registry adverse events: mortality, serious, and selected other adverse events
Adverse event (affected / at risk)Full dose LSD (200 mcg), stage 1Active placebo LSD (20 mcg), stage 1Full dose LSD (200 mcg), stage 2
All-cause mortality“1/8 (12.50%)”“0/4 (0.00%)”“0/3 (0.00%)”
Serious adverse events, total“1/8 (12.50%)”“1/4 (25.00%)”“0/3 (0.00%)”
Serious: metastatic esophageal cancer“1/8 (12.50%)”“0/4 (0.00%)”“0/3 (0.00%)”
Serious: pyelonephritis“0/8 (0.00%)”“1/4 (25.00%)”“0/3 (0.00%)”
Other adverse events, total“8/8 (100.00%)”“4/4 (100.00%)”“3/3 (100.00%)”
Feeling cold“6/8 (75.00%)”“0/4 (0.00%)”“1/3 (33.33%)”
Illusions“6/8 (75.00%)”“1/4 (25.00%)”“2/3 (66.67%)”
Emotional distress“5/8 (62.50%)”“1/4 (25.00%)”“0/3 (0.00%)”
Feeling abnormal“5/8 (62.50%)”“2/4 (50.00%)”“1/3 (33.33%)”
Time perception altered“4/8 (50.00%)”“0/4 (0.00%)”“2/3 (66.67%)”
Mydriasis“3/8 (37.50%)”“0/4 (0.00%)”“0/3 (0.00%)”
Anxiety“2/8 (25.00%)”“2/4 (50.00%)”“1/3 (33.33%)”
Impaired gait“2/8 (25.00%)”“0/4 (0.00%)”“2/3 (66.67%)”
Hallucination“1/8 (12.50%)”“0/4 (0.00%)”“0/3 (0.00%)”
Study limitations
Summary

LDA1 was a phase 2 pilot trial at one private practice in Solothurn, Switzerland, with the Multidisciplinary Association for Psychedelic Studies (MAPS) named as main sponsor; MAPS co-funded the trial, and the funding statement names two MAPS employees. Twelve participants with anxiety associated with life-threatening diseases were randomized to LSD 200 μg (8 participants) or an active placebo of LSD 20 μg (4 participants); one active placebo participant was excluded from analysis after a correction of the qualifying diagnosis, leaving 8 and 3 participants. The authors state that the sample size was sufficient for a study primarily focused on safety and feasibility and that the limited sample reduced precision in effect size estimates and significance testing.

With the alpha level adjusted to 0.025 for multiplicity, the reduction in state anxiety (p = 0.021) met the threshold and the reduction in trait anxiety (p = 0.033) did not. Only three of eight participants in the 200 μg group fell below the threshold of 40 on each subscale. The assessment 1 week after the second session was dropped for all participants because results were missing for two participants, and secondary outcomes were not tested for significance. The 12-month comparisons included participants who received 200 μg in the open-label crossover and had no concurrent control, and the qualitative follow-up tested 10 participants.

Blinding was not maintained: for all 24 blinded sessions, all participants correctly guessed the dose, and the authors state that the 20-μg dose was too low to achieve uncertainty about the dose. Half of the participants received a SCID diagnosis of generalized anxiety disorder, and the authors state that this does not mean the participants had the conventional pattern of psychopathology usually associated with GAD, because the SCID items do not differentiate GAD from a reaction to a life-threatening disease. The registry lists the illnesses as metastatic breast carcinoma (4 participants), metastatic gastric carcinoma (2), and plasmocytoma, non-Hodgkin's lymphoma, celiac disease, Parkinson's disease, and Bechterew's disease (1 each); mean age was 51.7 years, 7 of 11 participants were male, and race and ethnicity were not collected. The authors state that the course of the somatic illness may affect psychological parameters independent of the intervention, and that the EORTC-QLQ focused on physical aspects and was insufficient for evaluating long-term psychological changes.

The intervention combined LSD capsules with two preparatory psychotherapy sessions, three drug-free integrative psychotherapy sessions after each experimental session, and a male and female co-therapist team, with 8-hour experimental sessions and an overnight stay. The publication reports no drug-related severe adverse events; the registry reports serious adverse events of metastatic esophageal cancer (1 of 8) and pyelonephritis (1 of 4) and all-cause mortality of 1 of 8 in the 200 μg group. The registry and the publication differ on two details: the registry requires a score of at least 40 on each part of the STAI and spaces sessions two to four weeks apart, while the publication states that participants scored greater than 40 on either the state or the trait scale and that sessions were 2 to 3 weeks apart.